An economic evaluation published in the Indian Journal of Medical Research has demonstrated that shorter, six-month all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are cost-effective and offer improved health outcomes compared to the c
Speaking at the inauguration of the three-day International Pharma and Healthcare Exhibition (IPHEX 2024) organized by the Pharma Export Promotion Council of India (CAPEXIL) and the Ministry of Commerce and Industry in Greater Noida, Uttar Pradesh, Prasada called on the Indian pharmaceuti